申请人:Cadieux Jean-Jacques
公开号:US20100240713A1
公开(公告)日:2010-09-23
This invention is directed to compounds of formula (I), wherein m, formula (II), R
1
, R
2
and R
3
are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.
本发明涉及式(I)的化合物,其中m、式(II)、R1、R2和R3如本文所定义,作为立体异构体、对映异构体、互变异构体或其混合物;或其药学上可接受的盐、溶剂或前药,用于治疗铁代谢紊乱。本发明还涉及包含该化合物的制药组合物以及使用该化合物治疗铁代谢紊乱的方法。